Subsequent studies demonstrated that the anti-tumor activity of LOX-PP is through the direct or indirect inhibition of the Hsp70 and the suppresion of the MAPK/ERK pathway [13,15], Akt, FGFRs, [16,17] RPTPĸ signaling [18], FAK [19], and others [20] depending on the cellular or cancer context [4,21]. This evidence concerns the gene LOX and neoplasm.